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Summary
A male patient with a germline mutation in MEN1 presented at the age of 18 with classical features of gigantism. 
Previously, he had undergone resection of an insulin-secreting pancreatic neuroendocrine tumour (pNET) at the age of 10 
years and had subtotal parathyroidectomy due to primary hyperparathyroidism at the age of 15 years. He was found to 
havesignificantlyelevatedserumIGF-1,GH,GHRHandcalcitoninlevels.PituitaryMRIshowedanoverallbulkyglandwith
a 3 mm hypoechoic area. Abdominal MRI showed a 27 mm mass in the head of the pancreas and a 6 mm lesion in the tail. 
Lanreotide-Autogel 120 mg/month reduced GHRH by 45% and IGF-1 by 20%. Following pancreaticoduodenectomy, four 
NETswereidentifiedwithpositiveGHRHandcalcitoninstainingandKi-67indexof2%inthelargestlesion.Thepancreas
tail lesion was not removed. Post-operatively, GHRH and calcitonin levels were undetectable, IGF-1 levels normalised and 
GH suppressed normally on glucose challenge. Post-operative fasting glucose and HbA1c levels have remained normal 
at the last check-up. While adolescent-onset cases of GHRH-secreting pNETs have been described, to the best of our 
knowledge,thisisthefirstreportedcaseofectopicGHRHinapaediatricsettingleadingtogigantisminapatientwith




should be addressed 




 • It is important to diagnose gigantism and its underlying cause (pituitary vs ectopic) early in order to prevent further 
growth and avoid unnecessary pituitary surgery. The most common primary tumour sites in ectopic acromegaly include 
the lung (53%) and the pancreas (34%) (1): 76% of patients with a pNET secreting GHRH showed a MEN1 mutation (1).
 • Plasma GHRH testing is readily available in international laboratories and can be a useful diagnostic tool in 
distinguishing between pituitary acromegaly mediated by GH and ectopic acromegaly mediated by GHRH. Positive 
GHRHimmunostainingintheNETtissueconfirmsthediagnosis.
 • Distinguishing between pituitary (somatotroph) hyperplasia secondary to ectopic GHRH and pituitary adenoma 
isdifficultandrequiresspecialistneuroradiologyinputandconsideration,especiallyintheMEN1setting.Itis
important to note that the vast majority of GHRH-secreting tumours (lung, pancreas, phaeochromocytoma) are 
expectedtobevisibleoncross-sectionalimaging(mediandiameter55mm)(1). Therefore, we suggest that a 
chest X-ray and an abdominal ultrasound checking the adrenal glands and the pancreas should be included in the 
routine work-up of newly diagnosed acromegaly patients.
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Introduction
Gigantism is a rare condition which is due, in most cases, 
to excess growth hormone (GH) in childhood leading to 
accelerated growth and increased height (as the epiphyseal 
plates are not fused). Pituitary gigantism and acromegaly 
are on a continuum with most patients with gigantism also 
showing acromegalic features such as coarse facial features 
or pronounced growth of hands and feet.
The majority of cases of gigantism/acromegaly are 
secondary to GH-secreting pituitary adenomas, which 
may be syndromic or non-syndromic. Syndromic 
causes include Carney complex, multiple endocrine 
neoplasia types 1 and 4, and the paraganglioma, 
phaeochromocytoma and pituitary adenoma association 
(3PAs). Non-syndromic causes include familial isolated 
pituitary adenoma secondary to germline AIP mutations 
or duplication of GPR101, causing X-linked acrogigantism 
(2, 3). However, gigantism can be a sign of other conditions 
as well (4, 5, 6). 
GH excess due to a growth hormone-releasing hormone 
(GHRH)-secreting tumour accounts for less than 1% of cases 
of acromegaly (1, 7). We describe here a rare case of gigantism 
due to childhood-onset GH excess secondary to GHRH 
secreted by a pancreatic neuroendocrine tumour (pNET) 
in a patient with MEN1. This is the first case of paediatric-
onset gigantism from ectopic GHRH in a MEN1 setting to 
be reported in the literature, to the best of our knowledge. 
Case presentation
An 18-year-old Caucasian male was referred for evaluation 
of accelerated growth velocity (Fig. 1). 
His medical history started at the age of 7 years, 
when he experienced increasingly frequent and recurrent 
tonic–clonic seizures. These were found to be related 
to hyperinsulinaemic hypoglycaemia (lowest glucose 
level: 1.5 mmol/L). MRI revealed a 1cm lesion in the 
pancreatic neck. At the age of 10, the patient underwent 
enucleation of the tumour. Histopathology revealed a 
well-differentiated NET strongly positive for proinsulin 
and insulin with a few scattered cells positive for glucagon, 
somatostatin and calcitonin. He developed multiple 
post-operative complications including abdominal 
haemorrhage, pancreatitis, septic shock, renal failure and 
encephalopathy, but he completely recovered.
At the age of 11, genetic testing revealed a heterozygous 
germline mutation in the MEN1 gene (c.249_252delGTCT, 
p.I85Sfs). His father carries the same mutation and has 
hyperparathyroidism as the only clinical manifestation. 
Several family members on his father’s side are under 
endocrine care for MEN1 syndrome.
At the age of 14 years, he was diagnosed with 
primary hyperparathyroidism secondary to parathyroid 
hyperplasia. He underwent a subtotal parathyroidectomy 
(three of four glands removed, right upper parathyroid left 
in place) and transcervical thymectomy. 
At first evaluation at the adult endocrine clinic 
at the age 18, he was noted to be 193.5 cm tall (>97th 
percentile, mid-parental height 175 cm). He was noted to 
have long and thin hands, UK shoe size 12 (increased by 
2 sizes in the 2 years prior to evaluation), dorsal kyphosis 
and hyperhidrosis. He did not complain of headaches, 
visual problems or sleeping problems, and went through 
puberty normally. His skin was normal. His face did not 
show prominence of eyebrows and chin or enlargement 
of tongue. Stretch marks on both shoulders and 
horizontally on the back were noted, possibly secondary to 
accelerated growth.
Investigations
At the age of 18, IGF-1 was 2xULN (970 µg/L, normal 
range 247–481, Fig. 2). Random morning GH levels were 
elevated at 39 µg/L with GH nadir during the oral glucose 
tolerance test (OGTT) 1.7 µg/L (<1). He had normal serum 
prolactin (213 mU/L, 0–324), TSH (1.12 mU/L, 0.3–4) and 
FT4 levels (15.7 pmol/L, 10.5–24.5). Fasting plasma GHRH 
was significantly elevated at 327 ng/L (<60, Biomnis, Lyon, 
France). Chromogranin A and gut peptide levels were 
normal (gastrin 5 pmol/L (<50), glucagon 13 pmol/L (<50), 
VIP 4 pmol/L (<30), pancreatic polypeptide 43 pmol/L 
(<300), chromogranin A 44 pmol/L (<60) and somatostatin 
54 pmol/L (<150). Calcitonin levels were noted to be 
elevated at presentation at 82 ng/L (<0.8–4). No thyroid 
parenchymal lesions were noted on ultrasound imaging. 
His corrected calcium was normal at 2.55 mmol/L (2.2–
2.6) with normal phosphate 1.19 mmol/L (0.8–1.5) but 
slightly elevated PTH of 8.4 pmol/l (1.6–6.7) and decreased 
25-OH vitamin D levels of 8 nmol/L (>50). His urinary 24-h 
calcium was increased at 13 mmol/L(2.5–7.5). Bone age 
of 19 years was noted on hand X-ray (within 2 s.d. from 
chronological age).
Abdominal MRI revealed two lesions in the pancreatic 
head and tail, measuring 27 mm (Fig. 3) and 6 mm, 
respectively (Table 1), in keeping with NETs. A pituitary 
MRI showed a diffusely enlarged gland and raised the 
possibility of a 3 mm microadenoma showing slightly 
reduced enhancement in the right inferolateral aspect of 
the anterior pituitary (Figs 4A and 5B). 
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Treatment
He was initially started on treatment with 120 mg 
Lanreotide-Autogel monthly (every 28 days) for 6 months 
with partial biochemical response of a random serum 
GH 2.21 µg/L, IGF-1 778 µg/L (1.6× ULN) and a 50% 
drop in GHRH to 180 ng/L (<60). He received vitamin D 
replacement. Following careful discussion of the various 
therapeutic options with the multi-disciplinary team and 
the patient and his family, he underwent a pylorus-sparing 
pancreatoduodenectomy and cholecystectomy with the 
removal of the head and neck of the pancreas, including 
the largest tumour leaving the pancreatic tail (including 
the 6mm lesion) intact. The operation and the post-
operative period was without complications. 
Figure 1
Patient'sgrowthchartuptotheageof18showingacceleratedgrowthvelocity.Hisfinalheight,193.5cm,iscorrespondingtoheightstandarddeviation
scores: UK Tanner Whitehouse for chronological age (18 years) +2.83, adjusted for parental height +2.87 and UK Cole: for chronological age (18 years) 
+2.34, adjusted for parental height +2.38.
Figure 2
IGF-1 levels of the patient during the clinical course.
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Histological examination identified four grade 1 
and 2 NETs in the pancreas, positive for synaptophysin 
and chromogranin (Table 1). There was no lymph node 
invasion. The largest tumour was a well-differentiated 
NET positive for GHRH, SSTR2 and calcitonin on 
immunohistochemistry with a Ki-67 index of 2% (Table 
1, Fig. 6). The GHRH and SSTR2 expression were strong 
but focal, with large negative areas and small areas with 
50–100% of positive cells. The immunohistological 
detection of somatostatin, insulin and GH was negative in 
the four tumours (Table 1).
Post-operatively, GHRH and calcitonin were 
undetectable with IGF-1 returning into the normal range 
(264 µg/L) and a nadir GH of 0.5 µg/L on the OGTT. Post-
operatively, mild left-sided intrahepatic duct dilatation 
was noted, which was secondary to a likely benign 
stricture at the entero-biliary anastomosis. Pituitary MRI 
showed a reduction in the height of the pituitary gland 
(Fig. 4C and D).
Outcome and follow-up
Following surgery, over the last 5 years the patient has 
remained largely asymptomatic. His main problems 
during follow-up had been related to recurrent kidney 
stones and he underwent successful extracorporeal shock 
wave lithotripsy to a right lower pole renal calculus. He 
was started on cinacalcet 30 mg, which was increased to 
30 mg twice a day, and vitamin D3 10 000 units weekly 
were continued. The most recent corrected calcium is 2.24 
mmol/L (2.2–2.6), phosphate 1.08 mmol/L (0.8–1.5), PTH 
10.4 pmol/L (1.6–6.9) and 25-OH vitamin D3 73 nmol/L. 
Urinary 24 h calcium output is 11.8 mmol/day (2.5–7.5). 
Figure 3
MRI abdomen at presentation with an arrow indicating the larger (27 mm) 
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Post-operative fasting glucose levels 5.3 mmol/L (4–5.4) 
and HbA1c (27 mmol/L) (20–41) have remained normal 
at the last check-up. The lesions in the tail of his pancreas, 
pituitary as well as a hyperplastic right lower parathyroid 
gland are stable in size over the last 5 years. A full summary 
of his latest follow-up and surveillance regimen with 
comparison to present clinical guidelines (8) is provided 
in Table 2. 
Discussion
We report the case of a now 24-year-old gentleman 
with gigantism, multiple pNETs, a possible pituitary 
microadenoma and parathyroid tumour and hyperplasia 
due to a germline mutation in MEN1. He had developed 
gigantism due to excess of GH and IGF-1 during childhood 
secondary to the secretion of GHRH by a pNET. Although 
this is the first reported case of gigantism in a paediatric 
setting due to ectopic GHRH in a patient with MEN1 
syndrome, ectopic GHRH secretion in an adolescent 
patient with MEN1 was included in a previous case series 
(9) and personal communication with Francoise Borson-
Chazot, France who confirmed gigantism in that case). 
Early detection of growth hormone excess is important 
as many of the effects of growth hormone cannot be 
reversed with treatment which aims to limit any further 
consequences (i.e. prevent further growth in the case of 
gigantism). 
Ectopic secretion of GHRH is a rare cause of GH excess, 
accounting for less than 1% of all cases of acromegaly (1, 7). 
Ectopic sources mainly include NETs, usually of pancreatic 
(34%) or bronchial origin (53%) (1, 9). Ectopic GHRH 
secretion by phaeochromocytomas has also been reported 
(4%) (1, 10, 11, 12). However, while ectopic acromegaly is an 
uncommon entity, its diagnosis is important for two main 
reasons: (i) avoidance of unnecessary pituitary surgery (13) 
and institution of appropriate management of the non-
pituitary NET and (ii) screening for associated syndromes 
such as MEN1. 
GHRH-secreting pNETs in the setting of MEN1 are 
well described (9, 14, 15, 16, 17), with one series showing 
76% of patients with a pNET secreting GHRH having 
MEN1 mutations (1). Determining whether acromegaly 
is of pituitary or non-pituitary origin can be difficult but 
is of paramount importance, as unnecessary pituitary 
surgery and consequent potential hypopituitarism 
should be avoided in patients with ectopic acromegaly. 
It is important to note that the vast majority of GHRH-
secreting tumours (lung, pancreas, phaeoechromocytoma) 
are expected to be visible on cross-sectional imaging 
(median diameter 55 mm) (1). Therefore, we suggest that 
a chest X-ray and an abdominal ultrasound checking the 
adrenal glands and the pancreas should be included in the 
routine work-up of newly diagnosed acromegaly patients. 
It is worth remembering that an elevated fasting plasma 
GHRH is specific for ectopic GHRH release (1, 13) and 
highly useful in this diagnostic setting and several assays 
are now available. Monitoring GHRH following treatment 
can help identify the persistence or recurrence of disease 
Figure 4
Coronal MRI pre- (A,B) and post-pancreatic (C,D) surgery showing 
shrinkage of the pituitary gland following surgery.
Figure 5
MRI with pituitary microadenoma (arrow), (A–B) before pancreas surgery 
(A: T1-weighted image, B: T2-weighted image) and (C–D) 4 years after 
pancreas surgery (C: post-gadolinium T1, D: T2).
Downloaded from Bioscientifica.com at 07/13/2021 03:16:06PM
via free access
V S Nadhamuni and others MEN1, GHRH and gigantism
DOI: 10.1530/EDM-20-0208
https://edm.bioscientifica.com/ 6
ID: 20-0208; June 2021
(1). In our patient’s case, GHRH was undetectable after 
a large pancreatic resection and the removal of a pNET 
secreting GHRH. GHRH positive cells can be scattered or 
located in sheets, especially in well-differentiated cells; 
therefore, a systematic GHRH immunostaining is needed 
in all tumour fragments to prove the pancreatic origin of 
the GHRH ectopic secretion.
With respect to imaging, pituitary (somatotroph) 
hyperplasia has been observed secondary to ectopic GHRH 
release (1, 7, 13, 18), which could be misinterpreted as a 
pituitary macroadenoma (1). Indeed, in many instances 
from the literature, an ectopic source for acromegaly was 
considered only after unnecessary pituitary surgery due to 
misinterpretation of pituitary hyperplasia as adenoma in 
the context of clinical and acromegaly and elevated GH and 
IGF-1 levels (7, 9, 13). Interpretation of pituitary imaging 
by an experienced neuro-radiologist may help avoid 
this situation. In our patient’s case, while the pituitary 
gland was clearly bulky (Figs 4 and 5), a possible pituitary 
microadenoma was also described. Due to the large lesion 
in the head of the pancreas and the elevated GHRH, we 
opted for pancreatic surgery initially, but could not be sure 
at the time if acromegaly would fully resolve after surgery. 
The pituitary lesion has remained stable, and might 
well represent a small non-functioning microadenoma, 
similarly to those observed in a surveillance study of MEN1 
patients (19). 
We found significantly elevated calcitonin levels in this 
patient. Calcitonin expression on immunohistochemistry 
was found in 11% of cases in a large study screening 229 
pNETs (20). It is unclear how often calcitonin-secreting 
pNETs occur in the setting of MEN1, although previous cases 
have been reported (21, 22, 23, 24), including a case with 
both GHRH and calcitonin secretion, similar to our case.
Figure 6
Representative images of the histopathology of the largest pNET. H&E, 4× (A) and 20× (B) power and immunohistochemistry for calcitonin (C), GHRH (D), 
Ki-67 (E), chromogranin A (F) and SSTR2 (G) (20×).
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To date, our patient has developed multiple NETs in the 
pancreas, six in total, with the removal of five through two 
surgical procedures. The possibility of total pancreatectomy 
was discussed with the patient as an option for managing 
the existing lesions as well as prophylaxis against any 
future lesions, but with the inevitable consequence of 
insulin-dependent diabetes. The patient decided against 
this option, given the need for life-long insulin treatment 
post-operatively. We continue to monitor the NET in the 
tail of the pancreas through biochemical assessment and 
surveillance imaging.
Timely diagnosis of MEN1 is important to improve 
disease outcomes and survival in patients as well as affected 
family members (25). A recent cohort study of Dutch MEN1 
patients investigating the lag time between diagnosis of 
MEN1 in index patients and their family members (non-
index patients) found that 10 patients (4% of non-index 
cases) died because of a MEN1-related cause that developed 
during or before the lag time (pre-diagnosis) (26). Patients 
should be managed by a multi-disciplinary team of relevant 
specialists experienced in the diagnosis and treatment of 
patients with endocrine tumours (8) in order to facilitate 
appropriate genetic screening of family members as well as 
ensure appropriate surveillance protocols are carried out in 
affected patients. 
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